Genetic analysis of the TP53 and EGFR genes in head and neck cancers

Yasuhiro Ebihara; Miwako Iwai; Masafumi Yoshida; Mizuo Ando; Takahiro Asakage; Tatsuya Yamasoba; Yoshinori Murakami

doi:10.5981/jjhnc.37.1

Genetic analysis of the TP53 and EGFR genes in head and neck cancers

Yasuhiro Ebihara, Miwako Iwai, Masafumi Yoshida, Mizuo Ando, Takahiro Asakage, Tatsuya Yamasoba, Yoshinori Murakami

Research output: Contribution to journal › Article › peer-review

Abstract

To identify useful molecular markers for the treatment of head and neck cancers (HNCs), mutations of the TP53 and EGFR genes were analyzed in 56 HNCs, including 39 head and neck squamous cell carcinomas (HNSCCs). No EGFR mutation was observed in the fragments of exons 18-21. By contrast, 17 of 39 (44%) HNSCCs, as well as 3 of 6 cases (50%) with salivary gland carcinoma showed TP53 mutation in the fragments of exons 5-9. The incidence of nonsense mutation was 47%, which was higher than that in previous reports in other countries, suggesting the presence of etiological factors characteristic to Japanese patients. Further clinical assessment, including drug response and prognosis, is required in HNSCCs carrying the null-type mutation of TP53.

Original language	English
Pages (from-to)	1-6
Number of pages	6
Journal	Japanese Journal of Head and Neck Cancer
Volume	37
Issue number	1
DOIs	https://doi.org/10.5981/jjhnc.37.1
Publication status	Published - 2011
Externally published	Yes

Keywords

EGFR
Head and neck cancer
Nonsense mutation
TP53

ASJC Scopus subject areas

Otorhinolaryngology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5981/jjhnc.37.1

Cite this

@article{98044c4133b44da6a94f36b86fcfa3a8,

title = "Genetic analysis of the TP53 and EGFR genes in head and neck cancers",

abstract = "To identify useful molecular markers for the treatment of head and neck cancers (HNCs), mutations of the TP53 and EGFR genes were analyzed in 56 HNCs, including 39 head and neck squamous cell carcinomas (HNSCCs). No EGFR mutation was observed in the fragments of exons 18-21. By contrast, 17 of 39 (44%) HNSCCs, as well as 3 of 6 cases (50%) with salivary gland carcinoma showed TP53 mutation in the fragments of exons 5-9. The incidence of nonsense mutation was 47%, which was higher than that in previous reports in other countries, suggesting the presence of etiological factors characteristic to Japanese patients. Further clinical assessment, including drug response and prognosis, is required in HNSCCs carrying the null-type mutation of TP53.",

keywords = "EGFR, Head and neck cancer, Nonsense mutation, TP53",

author = "Yasuhiro Ebihara and Miwako Iwai and Masafumi Yoshida and Mizuo Ando and Takahiro Asakage and Tatsuya Yamasoba and Yoshinori Murakami",

year = "2011",

doi = "10.5981/jjhnc.37.1",

language = "English",

volume = "37",

pages = "1--6",

journal = "Japanese Journal of Head and Neck Cancer",

issn = "1349-5747",

publisher = "Nihon Tokeibu Gan Gakkai",

number = "1",

}

TY - JOUR

T1 - Genetic analysis of the TP53 and EGFR genes in head and neck cancers

AU - Ebihara, Yasuhiro

AU - Iwai, Miwako

AU - Yoshida, Masafumi

AU - Ando, Mizuo

AU - Asakage, Takahiro

AU - Yamasoba, Tatsuya

AU - Murakami, Yoshinori

PY - 2011

Y1 - 2011

N2 - To identify useful molecular markers for the treatment of head and neck cancers (HNCs), mutations of the TP53 and EGFR genes were analyzed in 56 HNCs, including 39 head and neck squamous cell carcinomas (HNSCCs). No EGFR mutation was observed in the fragments of exons 18-21. By contrast, 17 of 39 (44%) HNSCCs, as well as 3 of 6 cases (50%) with salivary gland carcinoma showed TP53 mutation in the fragments of exons 5-9. The incidence of nonsense mutation was 47%, which was higher than that in previous reports in other countries, suggesting the presence of etiological factors characteristic to Japanese patients. Further clinical assessment, including drug response and prognosis, is required in HNSCCs carrying the null-type mutation of TP53.

AB - To identify useful molecular markers for the treatment of head and neck cancers (HNCs), mutations of the TP53 and EGFR genes were analyzed in 56 HNCs, including 39 head and neck squamous cell carcinomas (HNSCCs). No EGFR mutation was observed in the fragments of exons 18-21. By contrast, 17 of 39 (44%) HNSCCs, as well as 3 of 6 cases (50%) with salivary gland carcinoma showed TP53 mutation in the fragments of exons 5-9. The incidence of nonsense mutation was 47%, which was higher than that in previous reports in other countries, suggesting the presence of etiological factors characteristic to Japanese patients. Further clinical assessment, including drug response and prognosis, is required in HNSCCs carrying the null-type mutation of TP53.

KW - EGFR

KW - Head and neck cancer

KW - Nonsense mutation

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=84870278624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870278624&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.37.1

DO - 10.5981/jjhnc.37.1

M3 - Article

AN - SCOPUS:84870278624

VL - 37

SP - 1

EP - 6

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 1

ER -

Genetic analysis of the TP53 and EGFR genes in head and neck cancers

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this